Loading
6 standard-of-care settings across 3 lines and 1 biomarker subgroup. Rows come from the cancer page's standard of care; the grid places each on its line and subgroup.
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|---|---|---|---|---|
| All comers | Diagnosis | Excisional node biopsy with expert haematopathology review to distinguish from classical Hodgkin lymphoma and T-cell/histiocyte-rich large B-cell lymphoma; FDG-PET/CT staging. | NCCN Guidelines: Hodgkin Lymphoma | 95 |
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|---|---|---|---|---|
| All comers | Relapse | Rebiopsy to exclude transformation; rituximab alone or with chemotherapy, radiotherapy for localised relapse; autologous transplantation only for early or repeated relapse. | NCCN Guidelines: Hodgkin Lymphoma | 93 |
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|---|---|---|---|---|
| All comers | Stage IA without risk factors | Involved-site radiotherapy alone (30 Gy); in children, complete excision followed by observation. | NCCN Guidelines: Hodgkin Lymphoma | 93 | |
| All comers | Stage IB to IV | ABVD or rituximab-containing chemotherapy (R-CHOP, R-CVP, R-ABVD) with or without involved-site radiotherapy; rituximab alone for frail patients. | NCCN Guidelines: Hodgkin Lymphoma | 93 | |
| All comers | Transformation | Treat as diffuse large B-cell lymphoma with R-CHOP. | NCCN Guidelines: Hodgkin Lymphoma | 84 | |
| All comers | Nodular lymphocyte-predominant Hodgkin lymphoma: a different disease that keeps the name | The malignant cell expresses CD20 and not CD30 or CD15, which is the opposite of classical Hodgkin lymphoma and the reason rituximab works and brentuximab vedotin does not. The WHO fifth edition renames it nodular lymphocyte-predominant B-cell lymphoma, which is a better description. It is indolent, affects men more than women, and relapses late. Stage IA disease without risk factors is treated with involved-site radiotherapy alone, typically 30 Gy, and a substantial proportion never relapse. Complete surgical excision of a single node followed by observation is used in children and in selected adults. More advanced disease is treated with rituximab-containing systemic treatment: R-CHOP, R-ABVD or bendamustine with rituximab, with or without radiotherapy to a residual site. A retrospective population series of 23 patients treated with bendamustine and rituximab in Alberta reported a response rate of 100 per cent, complete response in 78 per cent, and four-year progression-free survival of 83 per cent and overall survival of 87 per cent, which is the kind of evidence this uncommon disease has. The long-term data make the central point about how gently it should be treated. Across 471 patients in the German Hodgkin Study Group HD7 to HD15 trials, ten-year progression-free survival was 75.5 per cent and overall survival 92.1 per cent, but second malignancies occurred in 10.2 per cent, and of 43 deaths only 10 were from the lymphoma against 20 from second cancers and 13 from possibly treatment-related conditions. Over-treatment, not the lymphoma, is the main threat to life here. Transformation to a T-cell/histiocyte-rich large B-cell lymphoma occurs in a minority and is treated as aggressive lymphoma. | Long-term follow-up of nodular lymphocyte-predominant Hodgkin lymphoma treated in the GHSG HD7 to HD15 trialsRituximabBendamustineR-CHOP (lymphoma chemoimmunotherapy)DoxorubicinCyclophosphamideVincristinePrednisoneIMRT / IGRT (modern external beam)Radiotherapy in lymphoma: involved-site fields, 24 Gy, 4 Gy and total skin electron therapyWatch and wait in lymphoma: when the right treatment is none yetLate effects of Hodgkin lymphoma treatment, and the follow-up that answers themSecondary malignancy (therapy-related cancer) | NCCN Hodgkin Lymphoma; ESMO; GHSG HD7 to HD15 long-term follow-up | 93 |
Lines and subgroups are parsed from the setting text of each standard-of-care row and can misclassify an unusual phrasing; the row’s own setting is always shown. Guideline chips reflect the NCCN category and ESMO-MCBS grade recorded on the cancer page, checked on its stated date. Not medical advice.